

ERA 3000

Dual Chamber Pacing System Analyzer (PSA)

1. 510(K) SUMMARY

Name and Address of Sponsor: BIOTRONIK, Inc.
6024 Jean Road
Lake Oswego, OR 97035

Establishment Registration Number: 1028232

Device Name: Proprietary Names: ERA 3000 Dual Chamber Pacing System Analyzer
Classification: Class II/III
Classification Name: External Pacemaker Pulse Generator [21 CFR 870.3600]
Pacemaker Electrode Function Tester [21 CFR 870.3630]
Pacemaker Generator Function Analyzer [21 CFR 870.3720]
Product Code: DTA

Date Prepared: July 12, 2002

General Description and Predicate Devices:

The ERA 3000 is a portable, dual chamber pacing system analyzer designed to test the electrical performance of the pulse generator and the pacing lead system at the time of pacemaker implantation and during invasive pacemaker troubleshooting or evaluation procedures. It can also operate as a temporary external pulse generator during the above mentioned procedures. The ERA 3000 utilizes a touch-proof configuration to help prevent hazardous connection between patients and electrical power sources.

BIOTRONIK proposes the following Pacing System Analyzer cleared through 510(k) notification as a predicate device for the ERA 3000 Pacing System Analyzer:

- BIOTRONIK's ERA 300 Pacing System Analyzer [#K964190, cleared 07-10-97]

Indications for Use:

The ERA 3000 is intended for use during invasive pacemaker procedures in the following activities:

- **Temporary External Pacing**
Provides temporary stimulation under DDD, DDI, DDO, VVI, VDD, VOO, AAI, AOO, or ODO modalities during implantable pacemaker procedures or physician evaluations.
- **Lead Threshold Determination**
Determines in situ lead characteristics of impedance, capture threshold, P/R wave amplitude and P/R wave slew rate. Determines the in vivo retrograde conduction time.
- **Pacemaker Function Test**
Tests and analyzes the in vitro operation of external or implantable pulse generators. Determines the following parameters: pulse amplitude and width, A/V delay, and rate/interval.

Name and Address of Manufacturing Site: BIOTRONIK GmbH & Co. (reg. no. 9610139)
Woermannkehre 1, 12359 Berlin, Germany
Phone: 011-49-30-689-05-304

Name and Address of Contract Manufacturing Site: BIOTRONIK AG (reg. no. 8043892)
Ackerstrasse 6, 8180 Bülach, Switzerland
Phone: 011-41-1-864-5169

Contact Person and Phone Number: Jon Brumbaugh
Director, Regulatory Affairs
Phone: (888) 345-0374
Fax: (503) 635-9936

2. INDICATIONS FOR USE

The ERA 3000 is intended for use during invasive pacemaker procedures in the following activities:

- **Temporary External Pacing**
Provides temporary stimulation under DDD, DDI, DDO, VVI, VDD, VOO, AAI, AOO, or ODO modalities during implantable pacemaker procedures or physician evaluations.
- **Lead Threshold Determination**
Determines in situ lead characteristics of impedance, capture threshold, P/R wave amplitude and P/R wave slew rate. Determines the in vivo retrograde conduction time.
- **Pacemaker Function Test**
Tests and analyzes the in vitro operation of external or implantable pulse generators. Determines the following parameters: pulse amplitude and width, A/V delay, and rate/interval.

See Appendix 1 for FDA's 510(k) Indications for Use Form.



JAN 27 2003

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Biotronik, Inc.
c/o Mr. Jon Brumbaugh
Director, Regulatory Affairs
6024 Jean Road
Lake Oswego, OR 97035

Re: K022360
Trade Name: Pacing System Analyzer
Regulation Number: 21 CFR 870.3720
Regulation Name: Tester, Pacemaker Electrode Function
Regulatory Class: Class III (three)
Product Code: DTA
Dated: October 31, 2002
Received: November 4, 2002

Dear Mr. Brumbaugh:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Page 2 – Mr. Jon Brumbaugh

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Bram D. Zuckerman". The signature is fluid and cursive, with a large initial "B" and "Z".

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

510(k) Number (if known): K022360

Device Name: ERA 3000 Pacing System Analyzer

Indications For Use:

The ERA 3000 is intended for use during invasive pacemaker procedures in the following activities:

• **Temporary External Pacing**

Provides temporary stimulation under DDD, DDI, DOO, VVI, VDD, VOO, AAI, AOO, or ODO modalities during implantable pacemaker procedures or physician evaluations.

• **Lead Threshold Determination**

Determines in situ lead characteristics of impedance, capture threshold, P/R wave amplitude and P/R wave slew rate. Determines the in vivo retrograde conduction time.

• **Pacemaker Function Test**


Tests and analyzes the in vitro operation of external or implantable pulse generators. Determines the following parameters: pulse amplitude and width, A/V delay, and rate/interval.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use Only

(Optional Format 3-10-98)



(Division Sign-Off)

Division of Cardiovascular Devices

510(k) Number K022360